- Home
- /
- News
- /
- Drug Trials
- /
- December 2009
Drug Trials News for December 2009
Cequent Pharmaceuticals, a biopharmaceutical company that develops products to deliver RNAi-based treatments for the prevention and treatment of human disease, announced recently that the FDA Center for Biologics Evaluation and Research has approved Cequent’s first investigational new drug (IND) application.
16 December, 2009
ThromboGenics NV announced recently that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) age-related macular degeneration.
15 December, 2009
Light Sciences Oncology is anticipating significant short-term progress in the company’s multi-front development of Aptocine™ (talaporfin sodium), a novel treatment for solid tumors and benign neoplasms, including BPH.
14 December, 2009
UK-based Synexus recruited in excess of 2000 children aged between five and ten weeks of age over the course of three months, making Synexus the largest single source of subjects for a Phase III trial that investigated a paediatric vaccine against rotavirus and involved more than 3167 children across South Africa.
01 December, 2009